The life sciences industry is entering a period where policy is no longer a downstream consideration—it is actively shaping the commercial trajectory of products from the earliest stages of development. The Policy-Driven PMA Pivot Series explores how evolving healthcare policy, reimbursement dynamics, and pricing pressures are fundamentally changing how pharmaceutical and biotech companies approach market access strategy.

Historically, pricing and access decisions were often optimized after clinical development milestones were defined. Today, that model is shifting. Manufacturers are increasingly required to incorporate policy signals, payer expectations, and regulatory constraints much earlier in the commercialization lifecycle. This shift is reshaping how value is defined, how evidence is generated, and how launch strategies are designed.

Across this series, we examine how these forces are converging to create a more complex and more interconnected commercialization environment—one where policy is not just a constraint, but a central driver of strategic decision-making.

Download the series today.